These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 31015807)

  • 41. Understanding Immune Responses to Lassa Virus Infection and to Its Candidate Vaccines.
    Murphy H; Ly H
    Vaccines (Basel); 2022 Oct; 10(10):. PubMed ID: 36298533
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Screening and Identification of Lassa Virus Entry Inhibitors from an FDA-Approved Drug Library.
    Wang P; Liu Y; Zhang G; Wang S; Guo J; Cao J; Jia X; Zhang L; Xiao G; Wang W
    J Virol; 2018 Aug; 92(16):. PubMed ID: 29899092
    [No Abstract]   [Full Text] [Related]  

  • 43. Lassa fever vaccine candidates: A scoping review of vaccine clinical trials.
    Sulis G; Peebles A; Basta NE
    Trop Med Int Health; 2023 Jun; 28(6):420-431. PubMed ID: 37095630
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lassa Virus Reverse Genetics.
    Martínez-Sobrido L; Paessler S; de la Torre JC
    Methods Mol Biol; 2017; 1602():185-204. PubMed ID: 28508222
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lassa Virus Treatment Options.
    Hansen F; Jarvis MA; Feldmann H; Rosenke K
    Microorganisms; 2021 Apr; 9(4):. PubMed ID: 33917071
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recombinant vesicular stomatitis virus-based dengue-2 vaccine candidate induces humoral response and protects mice against lethal infection.
    Lauretti F; Chattopadhyay A; de Oliveira França RF; Castro-Jorge L; Rose J; Fonseca BA
    Hum Vaccin Immunother; 2016 Sep; 12(9):2327-33. PubMed ID: 27185081
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Improving the Breadth of the Host's Immune Response to Lassa Virus.
    Zapata JC; Medina-Moreno S; Guzmán-Cardozo C; Salvato MS
    Pathogens; 2018 Oct; 7(4):. PubMed ID: 30373278
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lassa fever: implications of T-cell immunity for vaccine development.
    ter Meulen J
    J Biotechnol; 1999 Aug; 73(2-3):207-12. PubMed ID: 10486929
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Animal Models of Lassa Fever.
    Sattler RA; Paessler S; Ly H; Huang C
    Pathogens; 2020 Mar; 9(3):. PubMed ID: 32155851
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An LASV GPC pseudotyped virus based reporter system enables evaluation of vaccines in mice under non-BSL-4 conditions.
    Li Q; Liu Q; Huang W; Wu J; Nie J; Wang M; Zhao C; Zhang L; Wang Y
    Vaccine; 2017 Sep; 35(38):5172-5178. PubMed ID: 28797730
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lassa fever-induced sensorineural hearing loss: A neglected public health and social burden.
    Mateer EJ; Huang C; Shehu NY; Paessler S
    PLoS Negl Trop Dis; 2018 Feb; 12(2):e0006187. PubMed ID: 29470486
    [TBL] [Abstract][Full Text] [Related]  

  • 52. General Molecular Strategy for Development of Arenavirus Live-Attenuated Vaccines.
    Iwasaki M; Ngo N; Cubitt B; Teijaro JR; de la Torre JC
    J Virol; 2015 Dec; 89(23):12166-77. PubMed ID: 26401045
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses.
    Pushko P; Geisbert J; Parker M; Jahrling P; Smith J
    J Virol; 2001 Dec; 75(23):11677-85. PubMed ID: 11689649
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Diagnostics for Lassa fever virus: a genetically diverse pathogen found in low-resource settings.
    Mazzola LT; Kelly-Cirino C
    BMJ Glob Health; 2019; 4(Suppl 2):e001116. PubMed ID: 30899575
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of Lassa virus vaccine immunogenicity in a CBA/J-ML29 mouse model.
    Goicochea MA; Zapata JC; Bryant J; Davis H; Salvato MS; Lukashevich IS
    Vaccine; 2012 Feb; 30(8):1445-52. PubMed ID: 22234266
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Development of an HIV vaccine using a vesicular stomatitis virus vector expressing designer HIV-1 envelope glycoproteins to enhance humoral responses.
    Racine T; Kobinger GP; Arts EJ
    AIDS Res Ther; 2017 Sep; 14(1):55. PubMed ID: 28893277
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Novel Tools for Lassa Virus Surveillance in Peri-domestic Rodents.
    Smither AR; Koninga J; Kanneh FB; Foday M; Boisen ML; Bond NG; Momoh M; Sandi JD; Kanneh L; Alhasan F; Kanneh IM; Yillah MS; Grant DS; Bush DJ; Nelson DKS; Cruz KM; Klitting R; Pauthner M; Andersen KG; Shaffer JG; Cross RW; Schieffelin JS; Garry RF
    medRxiv; 2023 Mar; ():. PubMed ID: 36993465
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vesicular Stomatitis Virus Pseudotyped with Ebola Virus Glycoprotein Serves as a Protective, Noninfectious Vaccine against Ebola Virus Challenge in Mice.
    Lennemann NJ; Herbert AS; Brouillette R; Rhein B; Bakken RA; Perschbacher KJ; Cooney AL; Miller-Hunt CL; Ten Eyck P; Biggins J; Olinger G; Dye JM; Maury W
    J Virol; 2017 Sep; 91(17):. PubMed ID: 28615211
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Use of a Scalable Replicon-Particle Vaccine to Protect Against Lethal Lassa Virus Infection in the Guinea Pig Model.
    Kainulainen MH; Spengler JR; Welch SR; Coleman-McCray JD; Harmon JR; Klena JD; Nichol ST; Albariño CG; Spiropoulou CF
    J Infect Dis; 2018 May; 217(12):1957-1966. PubMed ID: 29800368
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effective vaccine for lassa fever.
    Fisher-Hoch SP; Hutwagner L; Brown B; McCormick JB
    J Virol; 2000 Aug; 74(15):6777-83. PubMed ID: 10888616
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.